Compass therapeutics presents data on ctx-8371, a bispecific antibody targeting pd-1 and pd-l1, at the 2022 aacr annual meeting

Boston, april 08, 2022 (globe newswire) -- compass therapeutics, inc. (nasdaq: cmpx), a clinical-stage oncology focused biotechnology company developing proprietary antibody-based therapeutics to treat multiple human diseases, today reported new preclinical data on ctx-8371, a next generation bispecific checkpoint inhibitor that simultaneously targets pd-1 and pd-l1 and exhibits a unique moa that involves cleavage of cell surface pd-1, at the american association for cancer research (aacr) annual meeting, which is being held april 8-13, 2022, at the ernest n. morial convention center in new orleans, louisiana (abstract number: 5027; session title: combination immunotherapies / therapeutic antibodies).
CMPX Ratings Summary
CMPX Quant Ranking